ENABLE-2 takes the lead in the pursuit of new antibiotics
The Swedish Research Council's investment in ENABLE-2 has, with support from Vinnova, launched with four projects that are considered very promising in the pursuit for new antibiotics. In the first round of admissions, two projects from Uppsala University, and one each from Linköping University and the biotech company QureTech Bio AB were selected for development.
Resistant bacteria are one of the biggest threats to our health, making the development of new antibiotics an urgent challenge for research. The Swedish Research Council is therefore investing SEK 25 million in ENABLE-2, a national continuation of the European collaboration ENABLE, which has developed several antibacterial drug Candidates. The coordinator for both initiatives is Anders Karlén, professor at Uppsala University's Faculty of Pharmacy.
“With the support of the Swedish Research Council, we continue to build on the very successful foundation we have laid during ENABLE, for the development of new antibiotics against WHO priority pathogens. Our current funding covers 2022, but our ambition is for ENABLE-2 to remain active longer than that, preferably in collaboration with funders and research environments in other European countries, and our launch and initial progress has been very positive,” states Diarmaid Hughes, co-coordinator for ENABLE-2.
ENABLE-2 provides project support both in the form of experimental work and antibacterial drug discovery expertise during the early stages of antibiotic development, and the initiative created great interest among researchers in both academia and biotech companies. An initial call generated several high-quality applications, among which an independent committee selected four proposals for inclusion in the platform. Two of the projects are resident at the Faculty of Pharmacy, Uppsala University.
“We have created a molecule with promising properties for continued chemical development. Via ENABLE-2, we have gained access to expertise and resources in the techniques required for early drug development. This is exactly the support we need to take the next step, and within a year I expect that we will be ready to take our concept further to in vivo proof-of-concept studies,” says research leader Luke Odell.
In the second Uppsala University project, which has been developed in ENABLE for more than two years, Anders Karlén and co-workers have identified a new compound class showing antibacterial efficacy in animal model tests.
“That we have been selected and given the opportunity to continue to refine these molecules in ENABLE-2 is absolutely crucial to be able to take this project further in the development chain towards a new antibiotic,” states Anders Karlén.
At Linköping University, a research group led by Frank Hernandez is developing a first-in-class antibiotic for treating multidrug-resistant bacteria. Their approach is a pro-drug system that targets the pathogenic bacteria in a specific manner, followed by the subsequent drug release.
“The ENABLE-2 program provides the platform for translating our research findings into a drug development program, with the potential to start human clinical trials in the coming years," says research group leader Frank Hernandez.
Innovative drug development is of course also conducted in the private sector, and through collaboration with Vinnova, small and medium sized companies can also access the ENABLE-2 platform. In the fourth project, QureTech Bio AB has discovered a new class of antibacterial compounds and has very well-developed chemistry to be able to change and improve these new antibacterials.
“The competent support provided by ENABLE-2 and the resources available are fantastic. This leads the development forward in a structured way and we will reach the next phase more efficiently," says Fredrik Almqvist, Research director at QureTech Bio AB.
Uppsala University's leading roles in ENABLE and the IMI AMR Accelerator project COMBINE have contributed to the University's Faculty of Pharmacy today being able to mobilise all the experience and expertise required to lead collaborations of this scope.
"The fact that we have now been funded by the Swedish Research Council to coordinate ENABLE-2 is a clear confirmation of the respect and trust we have developed in the field of antibiotic discovery and development," says Anders Karlén.
- ENABLE-2 is a national platform that offers project support for the development of antibacterial drugs.
- ENABLE-2 is funded with SEK 25 million by the Swedish Research Council
- SMEs receiving positive evaluation from ENABLE-2 can apply for funding from Vinnova
- ENABLE-2 is coordinated at the Faculty of Pharmacy, Uppsala University.
- ENABLE was initiated in 2014 through the Innovative Medicines Initiative, a collaboration between the European Commission and the European pharmaceutical industry with the aim of taking a drug candidate all the way to testing on humans. By the end of the project in October 2021, several promising Lead and Candidate molecules had been developed and one Candidate had completed a Phase I study with a positive outcome.
Anders Karlén, coordinator, Professor
The Faculty of Pharmacy
text: Magnus Alsne, photo: Mikael Wallerstedt, Uppsala University
Anders Karlén guest in Forskarpodden: The Fight Against Antibiotic Resistance
2022-11-21In The Fight against Antibiotic Resistance, the new episode of Forskarpodden, Anders Karlén, Professor and Coordinator of ENABLE-2, and Dan I Andersson, Professor of Medical Bacteriology, discuss the current efforts at Uppsala University to fight the...
Luke Odell promoted to Professor of Medicinal Chemistry
2022-11-14The Faculty of Pharmacy congratulates Luke Odell on his promotion to Professor of Medicinal Chemistry at Uppsala University. “Research is a joint effort, so this is a recognition that our entire team can take pride in,” states Luke Odell. ...
SRC investing SEK 12 million in the Department’s research
2022-11-10Lindon Moodie, Luke Odell and Anna Orlova at the Department of Medicinal Chemistry receive grants amounting to more than SEK 12 million in the Swedish Research Council's calls in Medicine and Health and Natural Sciences and Engineering in 2022. ...
PhD thesis introducing new method to analyze potential vaccines
2022-10-28Lack of effective analytical tools to assess the safety and effectiveness of new vaccines often consumes unnecessarily large resources. In a new PhD thesis, Lars Geurink applies Capillary Electrophoresis and Analytical Quality by Design to develop CE...
Numerous new findings by SweDeliver's junior researchers
2022-10-18During summer and autumn, Ires van der Zwaan, Marcus Wanselius, Ann-Christin Jacobsen and numerous other junior researchers at SweDeliver are publishing results that add valuable knowledge to the fields of drug delivery. ...
Olof Eriksson receives the Johnny Ludvigsson Award 2022
2022-10-18Olof Eriksson, researcher at the Department of Medicinal Chemistry, is the receiver of the Johnny Ludvigsson Award 2022 and SEK 50,000. "Winning this award makes me feel that you can really make a difference for all the families out there who live wi...
ENABLE-2 expands its operations with a fifth development program
2022-10-07National platform ENABLE-2 continues to expand its project portfolio with a fifth development program in order to assist Thioredoxin Systems AB throughout the development of their EbsArgent product. ...
ULLA Summer School 22 a successful chapter in a 30-year tradition
2022-09-12After last year's online event, the Faculty of Pharmacy was finally able to welcome a new generation of pharmaceutical experts to ULLA Summer School 2022, and the experience received high marks from its international guests. ...
Uppsala University ranks 23rd in the world in Pharmacy & Pharmaceutical Sciences
2022-08-17The 2022 Academic Ranking of World Universities is official: Uppsala University continues to climb in the field of Pharmacy & Pharmaceutical Sciences and now ranks 23rd in the world. "This is yet another acknowledgment that our determined work is fru...
Nominate your candidate for the Scheele Award 2023
2022-08-12You can now nominate your candidate for the Scheele Award, the Swedish Academy of Pharmaceutical Sciences prize acknowledging prominent pharmaceutical researchers whose discoveries are important for pharmaceutical development and drugs of the future....
Many new publications by SweDeliver's junior researchers
2022-06-21During the spring and early summer, Staffan Berg, Vahid Forooqi Motlaq, Ann-Sofie Persson, Maryam Tofiq and numerous other junior researchers at SweDeliver are publishing results that add valuable knowledge to the fields of drug delivery. ...
New Podcast: SweDeliver at the Speed Of Life
2022-06-20Meet Center directors Christel Bergström, SweDeliver, and Cecilia Persson, AM4Life, in a special edition of STUNS podcast Speed of life, discussing the possibilities and challenges that come with coordinating world leading research and competence cen...
Researcher profile: Anders Karlén coordinates the combat against the invisible enemy
2022-06-09“As long as disaster does not strike with full force, many prefer to look elsewhere,” says Anders Karlén, Professor of Computer-Aided Drug Design, who after coordinating the European flagship ENABLE now continues the fight against antibiotic-resistan...
New thesis with focus on microgels as tools for drug delivery
2022-05-24Tuesday 14 June Yassir Al-Tikriti, PhD student at SweDeliver and Uppsala University’s Department of Medicinal Chemistry, will present his thesis Microgels as drug delivery vehicles: Loading and release of amphiphilic drugs. ...
Innovation award to new molecules for drugs against covid-19
2022-05-24With the Attractive Innovation Project Award, the researchers behind CoLD Therapeutics are taking the next step in turning their newly developed substances into a pharmaceutical drug against covid-19. "Our project is attracting a lot of attention and...
The Faculty of Pharmacy congratulates its new doctors
2022-05-19In May, Uppsala University traditionally holds a Doctoral Degree Conferment Ceremony, a celebration for those who have received doctorates during the year. This year, the promotion takes place on both 18 and 25 May, since the January promotion had to...
The Faculty of Pharmacy ready for ULLA Summer School 22
2022-05-11In early July, Uppsala University’s Faculty of Pharmacy welcomes PhD students and researchers from all over Europe to the ULLA Summer School 22, a unique experience that will bring together the future leaders in international pharmacy. ...
Several new publications from SweDeliver's junior researchers
2022-04-21SweDeliver continues to conduct high quality research. In the spring of 2022, Vicky Barmpatsalou, Ilse Dubbelboer, Agnes Rodler and Yassir Al-Tikriti are publishing articles that add important knowledge to the field of parenteral and oral drug delive...
ENABLE-2 takes the lead in the pursuit of new antibiotics
2022-03-21The Swedish Research Council's investment in ENABLE-2 has, with support from Vinnova, launched with four projects that are considered very promising in the pursuit for new antibiotics. In the first round of admissions, two projects from Uppsala Unive...
Insects in the Fyris river carried 33 different pharmaceutical substances
2022-03-18In a study of insects in the Fyris river, researchers identified traces of 33 different pharmaceutical substances. "In combination, these substances can give unexpected and amplified effects that, when they reach further up the food chain, might also...
New substances to provide better diagnosis and treatment of prostate cancer
2022-03-03Researchers at Uppsala University have developed two new substances that show positive results for early detection of metastases in prostate cancer. "If only one of our two leads is successful, we hope to be able to help all men suffering from prosta...
PhD Student competition: Present your research in three minutes
2022-03-02All PhDs students at the Faculty of Pharmacy and Uppsala University are invited to participate in the qualifying round for a competition where you present your research in a maximum of three minutes. The competition is organised by the Coimbra intern...
Faculty of Pharmacy welcomes 200 PhD students to ULLA 22
2022-02-10July 2–9, the Faculty of Pharmacy will be at the center of European pharmaceutical research when Uppsala University hosts the ULLA Summer School. "I am sure that we will all experience a unique summer school that adds important values to both tra...
New results on stabilising the boundary between collapsed and swollen phases in microgels
2022-02-01In a new article published in Gels, Yassir Al-Tikriti, PhD student at SweDeliver and the Department of Medicinal Chemistry, presents results supporting the hypothesis that the boundary between collapsed and swollen phases in the same microgel is stab...
ENABLE-2 ready to lead continued development of new antibiotics
2021-12-21ENABLE, the EU initiative for antibiotic development led by Uppsala University, will continue its work in ENABLE-2 with financial support from the Swedish Research Council. "An independent committee have chosen between many interesting project propos...
Experts in pharmaceuticals are positive about future virus control
2021-12-20“There is much to suggest that in the near future we can fight infectious viruses much faster than today”, says Anders Hallberg, medicinal chemist at Uppsala University and member of the Royal Swedish Academy of Science and its expert group, who in a...
Several new publications by SweDeliver's junior researchers
2021-12-13SweDeliver's PhD students and postdocs continue to conduct studies of very high quality. In the autumn of 2021, Vicky Barmpatsalou, Staffan Berg, Vahid Forooqi Motlaq and Irès van der Zwaan have all presented interesting publications. ...
Present your research at SciFest 2022 – Registration open now
2021-11-01The Uppsala science festival SciFest returns to Fyrishov. 10–12 March 2022, researchers from Uppsala University and thousands of curious schoolchildren and adults will meet for a variety of activities, shows and lectures. As a researcher at the Facul...
SEK 25 million to ENABLE-2 and continued development of new antibiotics
2021-10-06ENABLE, the EU initiative for antibiotic development led by Uppsala University, has received SEK 25 million from the Swedish Research Council to start up ENABLE-2. "We are already accepting project proposals and hope that this investment will inspire...
MSI Lab Per Andrén joins SciLifeLab Spatial Omics
2021-09-16With the launch of national resource Spatial Omics, SciLifeLab consolidates Sweden's advanced position in one of the hottest fields of science. "This gives us the capacity to extract even more detailed knowledge from cell and tissue analyses," states...
Webinar about your possibilities at Testa Center
2021-09-14Testa Center provides Uppsala University’s researchers access to state-of-the-art equipment for drug and bioprocess development. At the webinar "Academic research in the Testa Center – A testing bed for upscaling your biological innovations", you w...
Andrea Benediktsdottir is awarded the Iris Scholarship for aspiring women
2021-08-13Andrea Benediktsdottir, PhD student at the Department of Medicinal Chemistry, is awarded the Iris Scholarship for aspiring women in Sweden. With the scholarship, Andrea Benediktsdottir will participate in an interdisciplinary course focusing on antib...
SciLifeLab – A national research infrastructure in Uppsala
2021-06-18SciLifeLab is a national research infrastructure in life sciences with Uppsala University as one of four host universities. Today, SciLifeLab conducts operations at most major Swedish universities. ...
New research to improve use of amphiphilic drug molecules
2021-05-19By exploring the aggregation properties of different amphiphilic molecules in microgels, Yassir Al-Tikriti, PhD student at the Department of Medicinal Chemistry, aims to provide tools and knowledge of importance for future cancer therapies and antide...
New seminar series puts focus on Swedish drug development
2021-04-19This spring semester, SweDeliver and NextBioForm invite to online lunch seminars. Welcome to experience frontline research with a focus on industrial challenges in drug delivery and the development of biologically based drugs. ...
Olof Eriksson receives SEK 1,3 million for PET project
2021-04-19Olof Eriksson, researcher in translational imaging, is awarded a Project Grant of SEK 1,303,000 from Diabetes Wellness Sweden for his project GPR44 as a PET marker for measuring beta cell mass in human. ...
New biomarkers can lead to breakthrough in diabetes research
2021-04-19With the discovery of two new biomarkers, Olof Eriksson, researcher in translational imaging, may lead the way to the scientific breakthrough that will enable curative drugs and personalised treatments for diabetes. ...
Apply for funding for postdoc exchange between the Faculty of Pharmacy and SLU
2021-04-19Funding is now available for two postdoc exchanges, one hosted by the Faculty of Pharmacy or Fauculty of Medicine at Uppsala University, and one by a department at the SLU Faculty of Veterinary Medicine and Animal Science ...
Here you can read more research news at the Department of Medicinal Chemistry